Endocrinology Research Analysis
April 2026 endocrinology delivered mechanistic-to-clinic advances spanning obesity, diabetes, and environmental endocrine risk. A Cell study uncovered a skin–hypothalamus KLK14–LRRC7 pathway that imprints prior heat exposure into durable metabolic vulnerability, reframing climate exposure as an endocrine risk factor. Two randomized human signals shaped obesity care: cagrilintide plus semaglutide outperformed semaglutide alone in a phase 3a East Asian trial, while a prespecified SELECT analysis r
Summary
April 2026 endocrinology delivered mechanistic-to-clinic advances spanning obesity, diabetes, and environmental endocrine risk. A Cell study uncovered a skin–hypothalamus KLK14–LRRC7 pathway that imprints prior heat exposure into durable metabolic vulnerability, reframing climate exposure as an endocrine risk factor. Two randomized human signals shaped obesity care: cagrilintide plus semaglutide outperformed semaglutide alone in a phase 3a East Asian trial, while a prespecified SELECT analysis reinforced semaglutide’s cardiometabolic and hepatic benefits in obesity at high fibrosis risk. Mechanistically, integrative CRISPR–QTL mapping nominated PDIA6/Golgi trafficking as key β-cell regulators of proinsulin, and metabolite-driven PPARγ HMGylation linked amino-acid metabolism to thermogenesis, expanding druggable targets. Emerging islet epigenomics and biomarker frameworks continue to enable earlier, tissue-informed risk stratification.
Selected Articles
1. A skin-hypothalamus axis couples heat stress and metabolic dysfunction.
Preclinical work in mice shows that prior environmental heat exposure raises skin-derived KLK14, which imprints hypothalamic signaling (involving LRRC7) and increases vulnerability to later obesogenic diet–induced metabolic dysfunction. The study defines a peripheral-to-central axis linking cumulative heat stress to durable metabolic susceptibility.
Impact: Identifies a novel, causal peripheral‑to‑brain pathway by which environmental heat stress durably increases metabolic disease risk — a potential paradigm shift linking climate/occupational exposures to endocrine disease mechanisms.
Clinical Implications: Although preclinical, the findings nominate KLK14–hypothalamic signaling as a mechanistic target and suggest that cumulative heat exposure may be a modifiable risk factor for metabolic disease; public‑health heat‑mitigation and further human validation are warranted.
Key Findings
- Prior heat exposure increased susceptibility to later diet‑induced metabolic dysfunction in mice.
- Heat stress elevated skin-derived KLK14 that imprinted hypothalamic signaling involving LRRC7.
- Defines a durable skin–hypothalamus axis linking environmental heat to metabolic vulnerability.
2. Proinsulin regulators identified with CRISPR screen and in vivo mouse QTL mapping.
A genome-wide CRISPR screen in β-cell lines identified 84 regulators of the intracellular proinsulin/insulin ratio and, when integrated with mouse plasma proinsulin QTL mapping, converged on Golgi trafficking as a central control axis and PDIA6 as a top convergent regulator. PDIA6 knockdown reduced proinsulin accumulation in Golgi/secretory granules without altering folding, impairing proinsulin production through a UPR-independent mechanism. Cross-species perturbations support PDIA6 and Golgi-trafficking as actionable targets for restoring proinsulin/insulin balance.
Impact: Provides a validated, mechanism-rich atlas of proinsulin regulation that nominates PDIA6 and Golgi-trafficking pathways as novel, actionable targets for β-cell dysfunction in diabetes — a high-impact mechanistic advance with translational potential.
Clinical Implications: PDIA6/Golgi-trafficking modulation may enable therapies that normalize proinsulin/insulin balance and improve glycemic control; these targets warrant validation in human islets and diabetic models and could inform biomarker development.
Key Findings
- Genome-wide CRISPR screen identified 84 regulators of intracellular proinsulin/insulin ratio.
- Functional annotation highlights Golgi trafficking as primary organelle axis controlling proinsulin storage and levels.
- Mouse QTL mapping converged on PDIA6; PDIA6 knockdown reduced Golgi/secretory granule proinsulin and impaired production via a UPR-independent mechanism.
3. Leucine catabolic enzyme AUH regulates BAT thermogenesis via PPARγ HMGylation and RNA-binding function in male mice.
AUH promotes thermogenesis by producing HMG-CoA that HMGylates PPARγ at K386 to enhance UCP1 transcription and by stabilizing Ucp1 mRNA via RNA binding; AUH overexpression induces browning and protects male mice from diet-induced obesity, linking leucine catabolism to adipose thermogenic control.
Impact: Identifies a previously unrecognized metabolite-driven post-translational modification (PPARγ HMGylation) that directly controls thermogenesis and nominates AUH/PPARγ HMGylation as a novel obesity therapeutic axis.
Clinical Implications: Although preclinical, targeting AUH activity or modulating PPARγ HMGylation could be explored to enhance brown/beige fat thermogenesis and energy expenditure in obesity; sex-specific effects require evaluation.
Key Findings
- AUH-derived HMG‑CoA HMGylates PPARγ at lysine 386, enhancing transcriptional activity and UCP1 expression.
- AUH binds and stabilizes Ucp1 mRNA via RNA-binding function, providing a second mechanism to increase UCP1.
- AUH overexpression induces browning and protects male mice from high‑fat diet–induced obesity; human WAT AUH inversely correlates with adiposity.
4. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
In a prespecified secondary analysis of the SELECT randomized trial (104-week follow-up), semaglutide reduced major adverse cardiovascular events in obese adults without diabetes who were at increased risk for liver fibrosis by FIB-4 criteria, and produced greater reductions in fatty liver index vs placebo. Effects were consistent across FIB-4 thresholds, supporting cardiometabolic and hepatic benefit in this subgroup.
Impact: Extends high-quality RCT evidence that GLP-1RA therapy confers cardiovascular benefit to obese patients at elevated liver-fibrosis risk and links metabolic liver improvement to reduced MACE, informing cross-disciplinary treatment prioritization.
Clinical Implications: Consider semaglutide for obese patients with elevated noninvasive fibrosis scores (e.g., FIB-4) even without diabetes when integrated cardiometabolic–hepatology benefit is a priority; validate fibrosis via imaging/biopsy when clinically indicated and monitor hepatic and cardiovascular endpoints.
Key Findings
- Prespecified SELECT subgroup analysis showed MACE reduction by 26% in patients with FIB-4 ≥1.3 (HR 0.74) and consistent benefit across age-specific FIB-4 thresholds.
- Semaglutide produced a 28% greater decrease in fatty liver index versus placebo over 104 weeks.
- Trend toward larger MACE reduction in the highest FIB-4 stratum (FIB-4 >2.67) though not statistically conclusive.
5. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
In a double‑blind, multicenter phase 3a RCT in Japan and Taiwan (n=331), fixed‑dose cagrilintide 2.4 mg plus semaglutide 2.4 mg produced −18.4% mean bodyweight change at 68 weeks versus −11.9% with semaglutide alone (ETD −6.5 percentage points; p<0.0001). Gastrointestinal adverse events were common but similar between groups; discontinuation rates were low.
Impact: Provides randomized, region‑specific, high-quality evidence that amylin pathway co‑agonism substantially augments GLP‑1–mediated weight loss, informing escalation strategies in obesity pharmacotherapy.
Clinical Implications: Supports considering cagrilintide plus semaglutide for adults with overweight/obesity (with or without T2D) seeking greater weight loss; clinicians should counsel on GI tolerability and monitor during titration and longer-term follow-up for cardiometabolic outcomes.
Key Findings
- Mean weight change at week 68: −18.4% (cagrilintide–semaglutide) vs −11.9% (semaglutide); ETD −6.5 percentage points (95% CI −8.4 to −4.6; p<0.0001).
- Adverse events were mainly gastrointestinal and similar in frequency across groups; discontinuations were 10% vs 6% (combination vs semaglutide).
- Trial conducted across Japan and Taiwan with 68-week follow-up, supporting regional generalizability.